The invention relates to racemic or enantiomerically pure 4-pyrrolidino
derivatives, processes for their preparation, pharmaceutical compositions
comprising said derivatives, and their use in the prevention and
treatment of illness, in particular which is mediated by monoamine
oxidase B inhibitors, in particular Alzheimer's disease or senile
dementia.